These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34762074)

  • 21. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    Carlo MI; Giri VN; Paller CJ; Abida W; Alumkal JJ; Beer TM; Beltran H; George DJ; Heath EI; Higano CS; McKay RR; Morgans AK; Patnaik A; Ryan CJ; Schaeffer EM; Stadler WM; Taplin ME; Kauff ND; Vinson J; Antonarakis ES; Cheng HH
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30761386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
    Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).
    Rathi N; Anderson N; Greenberg S; Vagher J; Agarwal N; Hahn AW
    World J Oncol; 2018 Aug; 9(4):119-122. PubMed ID: 30220950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
    Frank S; Nelson P; Vasioukhin V
    F1000Res; 2018; 7():. PubMed ID: 30135717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.
    LeVee A; Lin CY; Posadas E; Figlin R; Bhowmick NA; Di Vizio D; Ellis L; Rosser CJ; Freeman MR; Theodorescu D; Freedland SJ; Gong J
    Onco Targets Ther; 2021; 14():4819-4832. PubMed ID: 34552338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
    Gourdin T
    Curr Opin Oncol; 2019 May; 31(3):188-193. PubMed ID: 30925537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 31. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    Brönimann S; Lemberger U; Bruchbacher A; Shariat SF; Hassler MR
    Curr Opin Urol; 2020 Jul; 30(4):519-526. PubMed ID: 32427631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    Castro E; Mateo J; Olmos D; de Bono JS
    Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.
    Modena A; Iacovelli R; Scarpa A; Brunelli M; Ciccarese C; Fantinel E; Bimbatti D; Massari F; Martignoni G; Tortora G
    Target Oncol; 2016 Oct; 11(5):569-577. PubMed ID: 27402433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
    Zhu J; Tucker M; Marin D; Gupta RT; Healy P; Humeniuk M; Jarvis C; Zhang T; McNamara M; George DJ; Wu Y; Lisi S; Armstrong AJ
    Urol Oncol; 2019 Nov; 37(11):813.e1-813.e9. PubMed ID: 31327751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
    Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
    J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
    Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.